Teva Research Institute in Japan
About Us
In 2025, Teva established a research institute in Tokyo, Japan. Led locally by Makoto Suzuki, PhD, the Teva Research Institute develops novel medicines to treat serious diseases with unmet needs in Japan. The institute is the newest among the company’s 20+ research sites across the world.
Makoto Suzuki, Japan Program Leader
Our Focus
The institute focuses on the development strategy for innovative medicines in the therapeutic areas of
neuroscience and immunology.
The team is part of a Phase 2 study multiple system atrophy (MSA), a rare, rapidly progressive and fatal neurogenerative disease.
Learn more about:
MSA | TOPAS-MSA Study |
Japan Registry of Clinical Trials
The team also completed a pivotal Phase 2 study for ulcerative colitis and Crohn’s disease, the two most common forms of inflammatory bowel disease (IBD).
Masahito Nagashima, Head of Japan Clinical Development
Experienced Leadership
Makoto and his leadership team have extensive experience engaging with the nation’s healthcare sector, including regulatory authorities and key opinion leaders. This strength will support the institute as it works to establish its presence, and become a key contributor to the health and well-being of Japanese patients and their families.
Working With Us
Working at Teva means being part of something bigger.
A shared purpose unites us to improve the lives of patients. We collaborate across the world to make good health more affordable and accessible to millions of people.
Our Culture
Our environment and culture combine the benefits of an established global biopharmaceutical company with those of a small and nimble startup.
We embrace fresh ideas and innovative approaches, fostering a spirit of openness and adaptability. Colleagues have the freedom to pursue various interests, stretch boundaries, and flourish both personally and professionally.
We are all in for better health and committed to the same ambitious goals: to build Teva’s reputation as a biopharma innovator and improve the lives of patients in Japan.
NPS-ALL-NP-01766 APRIL 2026